摘要:
A composition for the transdermal delivery of a biologically active peptide having a molecular weight of about 5,000 or less comprising at lest one biologically active peptide, at least one higher alcohol, ester and/or higher amide in combination with at least one pyrrolidone compound of the formula: ##STR1## where R.sub.5 is hydrogen or a lower alkyl group having 1 to 4 carbon atoms, R.sub.6 is hydrogen or a lower alkyl group having 1 to 3 carbon atoms and n is 3, 4 or 5. A method for percutaneously administering such a composition is also disclosed.
摘要:
A method of percutaneously administering a physiologically active agent which comprises applying to the skin of a mammal a physiologically active agent in a carrier system which comprises at least one adjuvant and at least one solvent. The adjuvant can be selected from higher monoalcohols or mixtures thereof. The solvent can be selected from thioglycerols, lactic acid and esters thereof, cyclic ureas, compounds represented by the general formula R.sub.1 R.sub.2 NCONR.sub.3 R.sub.4, pyrrolidone-type compounds, amides, lactones or mixtures thereof.
摘要翻译:一种经皮给药生理活性剂的方法,其包括向包含至少一种佐剂和至少一种溶剂的载体体系中的哺乳动物的皮肤施用生理活性剂。 佐剂可以选自更高级的一元醇或其混合物。 溶剂可以选自硫代甘油,乳酸及其酯,环脲,由通式R 1 R 2 NCONR 3 R 4表示的化合物,吡咯烷酮型化合物,酰胺,内酯或其混合物。
摘要:
A method of percutaneously administering a physiologically active agent which comprises applying to the skin of a mammal a physiologically active agent in a carrier system which comprises at least one adjuvant and at least one solvent. The adjuvant can be selected from aliphatic hydrocarbons, halogen substituted aliphatic hydrocarbons, alcohol esters of aliphatic carboxylic acids, mono- or di-ethers, ketones, or mixtures thereof. The solvent can be selected from thioglycerols, lactic acid and esters thereof, cyclic ureas, compounds represented by the general formula R.sub.1 R.sub.2 NCONR.sub.3 R.sub.4, pyrrolidone-type compounds, amides, lactones or mixtures thereof.
摘要翻译:一种经皮给药生理活性剂的方法,其包括向包含至少一种佐剂和至少一种溶剂的载体体系中的哺乳动物的皮肤施用生理活性剂。 佐剂可以选自脂族烃,卤素取代的脂族烃,脂族羧酸的醇酯,单醚或二醚,酮或其混合物。 溶剂可以选自硫代甘油,乳酸及其酯,环脲,由通式R 1 R 2 NCONR 3 R 4表示的化合物,吡咯烷酮型化合物,酰胺,内酯或其混合物。
摘要:
A method of percutaneously administering a physiologically active agent which comprises applying to the skin of a mammal a physiologically active agent in a carrier system which comprises at least one adjuvant, at least one solvent and at least one diol and/or triol moderator. The adjuvant can be selected from aliphatic hydrocarbons, halogen substituted aliphatic hydrocarbons, alcohol esters of aliphatic carboxylic acids, mono- or di-ethers, ketones, higher monoalcohols or mixtures thereof. The solvent can be selected from thioglycerols, lactic acid and esters thereof, cyclic ureas, compounds represented by the general formula R.sub.1 R.sub.2 NCONR.sub.3 R.sub.4, pyrrolidone-type compounds, amides, lactones or mixtures thereof.
摘要翻译:一种经皮施用生理活性剂的方法,其包括将至少一种佐剂,至少一种溶剂和至少一种二醇和/或三醇调节剂施用于载体体系中的哺乳动物皮肤上的生理活性剂。 佐剂可以选自脂族烃,卤素取代的脂族烃,脂族羧酸的醇酯,单醚或二醚,酮,高级一元醇或其混合物。 溶剂可以选自硫代甘油,乳酸及其酯,环脲,由通式R 1 R 2 NCONR 3 R 4表示的化合物,吡咯烷酮型化合物,酰胺,内酯或其混合物。
摘要:
A method of percutaneously administering metoclopramide which comprises applying to the skin of a mammal metoclopramide in a carrier system which comprises at least one adjuvant and at least one solvent. The adjuvant is a monovalent alcohol ester of an aliphatic monocarboxylic acid or an aliphatic monoalcohol. The solvent is a pyrrolidone-type compound. Mixtures can also be used.
摘要:
A method of percutaneously administering a physiologically active agent which comprises applying to the skin of a mammal a physiologically active agent in a carrier system which comprises at least one adjuvant and at least one solvent. The adjuvant can be selected from higher monoalcohols or mixtures thereof. The solvent can be selected from thioglycerols, lactic acid and esters thereof, cyclic ureas, compounds represented by the general formula R.sub.1 R.sub.2 NCONR.sub.3 R.sub.4, pyrrolidone-type compounds, amides, lactones or mixtures thereof.
摘要翻译:一种经皮给药生理活性剂的方法,其包括向包含至少一种佐剂和至少一种溶剂的载体体系中的哺乳动物的皮肤施用生理活性剂。 佐剂可以选自更高级的一元醇或其混合物。 溶剂可以选自硫代甘油,乳酸及其酯,环脲,由通式R 1 R 2 NCONR 3 R 4表示的化合物,吡咯烷酮型化合物,酰胺,内酯或其混合物。
摘要:
A semi-solid delivery vehicle contains a polyorthoester and an excipient, and a semi-solid pharmaceutical composition contains an active agent and the delivery vehicle. The pharmaceutical composition may be a topical, syringable, or injectable formulation; and is suitable for local delivery of the active agent. Methods of treatment are also disclosed.
摘要:
Amphiphilic copolymer, containing at least a hydrophilic chain segment (A) and a hydrophobic chain segment (B), wherein the hydrophilic chain segment (A) contains peptides and wherein the hydrophobic chain segment (B) contains acetal groups or orthoester groups. The hydrophilic chain segment (A) preferably contains glutamine/glutamic acid units or asparagines/aspartic acid units, making a biodegradable copolymer which can form a thermogel.
摘要:
A pharmaceutical composition for the sustained release of an effective amount of a selective 5-hydroxytryptamine 3 (5-HT3) receptor antagonist for the prevention, reduction or alleviation of acute and delayed chemotherapy-induced nausea and vomiting (CINV) following a course of emetogenic chemotherapy, wherein the composition is administered by subcutaneous injection, the composition comprising a 5-HT3 receptor antagonist, a semi-solid delivery vehicle and a pharmaceutically acceptable liquid excipient; wherein the composition, when administered in a single dosage, provides a controlled release of the 5-HT3 receptor antagonist and prolonging the release of the 5-HT3 receptor antagonist that tracks the profile of the incidence of vomiting.
摘要:
The present invention provides graft copolymer delivery vehicle which comprises a polyethyleneglycol (PEG)-polyacetal (PA) copolymer or a polyethyleneglycol (PEG)-polyacetal (PA)-polyorthoester (POE) copolymer. The polyethyleneglycol-polyacetal graft copolymers or the polyethyleneglycol-polyacetal-polyorthoester graft copolymers, in particular, the PA-g-PEG or the PA-POE-g-PEG suitable for the invention are represented by Formulae I and V: